Drug Utilization Review (DUR) Meeting Minutes
March 8, 2010

Members Present: Patricia Churchill, Norman Byers, Carrie Sorenson, Greg Pfister, Jeffrey Hostetter, John Savageau, Carlotta McCleary, David Clinkenbeard, Steve Irsfeld, Russ Sobotta, James Carlson, Cheryl Huber, Kim Krohn, Todd Twogood
Members Absent: Leann Ness, Gary Betting
Medicaid Pharmacy Department: Brendan Joyce
HID Staff Present: Candace Rieth

Chair, J. Hostetter called the meeting to order at 1:07 pm. Chair, J. Hostetter asked for a motion to approve the minutes from the December meeting. N. Byers moved that the minutes be approved and C. Sorenson seconded the motion. Chair, J. Hostetter called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update
B. Joyce informed the board that the budget remains flat from last quarter.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Antihistamine, PPI, COX-II/NSAID, Revatio/Adcirca, Actoplus Met and Ophthalmic Anti-infective forms and criteria were reviewed. Changes were made to the PPI and COX-II/NSAID forms and criteria. The PPI form/criteria will reflect the addition of Prevacid 24 to the list of step one medications and the addition of lansoprazole and pantoprazole to the list of step two medications. The NSAID form/criteria will reflect that Solaraze be approved with an indication of actinic keratosis and that a trial of Voltaren gel will be required prior to approval of Flector. All other forms and criteria will remain the same.

Intuniv Review
Brendan reviewed Intuniv utilization in North Dakota. Currently, there are several edits in place regarding Intuniv; quantity limits, drug-drug (with IR tablets) and age limit of 6-17. The board asked that additional information be brought to the next meeting including the specialty of providers currently prescribing Intuniv as well as any studies of guanfacine IR in children that are available. There was no public comment.

Xolair Review
Brendan reviewed Xolair utilization. The board suggested that Xolair have a patient safety model similar to hemophilia to ensure compliance. The board asked that a review of all specialty medications suitable for criteria based prior authorizations be reviewed and presented with Xolair at the next board meeting. L. Ding of Genentech spoke on behalf of Xolair.

Suboxone/Subutex Review
Brendan reviewed Suboxone and Subutex utilization with the board. After discussion, J. Savageau made a motion to place Suboxone and Subutex on prior authorization. K. Krohn seconded the motion. This topic will be brought up at the next meeting for finalization. There was no public comment.

Elidel/Protopic Review
Brendan reviewed Elidel and Protopic utilization. Currently, there is an edit in place to prevent use of both products consecutively. L. Pukrabek of Astellas spoke on behalf of Protopic. Board members tabled the discussion of Elidel and Protopic.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. C. Huber moved to approve the new criteria and G. Pfister seconded the motion. Chair, J. Hostetter called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 14, 2010. C. Huber made a motion to adjourn the meeting. C. Sorenson seconded. The motion passed with no audible dissent. Chair J. Hostetter adjourned the meeting at 3:15 pm.